In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/ erlotinib or lapatinib alone: Implication of receptors' down-regulation and dimers' disruption

✍ Scribed by Larbouret, Christel (author);Gaborit, Nadège (author);Chardès, Thierry (author);Coelho, Mickaël (author);Campigna, Emmanuelle (author);Bascoul-Mollevi, Caroline (author);Mach, Jean Pierre (author);Azria, David (author);Robert, Bruno (author);Pèlegrin, André (author)

• Book ID: 122155256
• Publisher: Elsevier B.V.
• Year: 2012
• Tongue: English
• Weight: 608 KB
• Volume: 14
• Category: Article
• ISSN: 1522-8002
• DOI: 10.1593/neo.111602